Report for: Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Title	Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
Published in	Trials, July 2020
DOI	10.1186/s13063-020-04608-4
Pubmed ID	32684162
Authors	Grazia Daniela Femminella, Eleni Frangou, Sharon B. Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H. Ridha, Carol Bannister, Zuzana Walker, Hilary Archer, Elizabeth Coulthard, Ben R. Underwood, Aparna Prasanna, Paul Koranteng, Salman Karim, Kehinde Junaid, Bernadette McGuinness, Ramin Nilforooshan, Ajay Macharouthu, Andrew Donaldson, Simon Thacker, Gregor Russell, Naghma Malik, Vandana Mate, Lucy Knight, Sajeev Kshemendran, John Harrison, Christian Hölscher, David J. Brooks, Anthony Peter Passmore, Clive Ballard, Paul Edison

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
United Kingdom	1	100%

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	9	100%

Readers by professional status	Count	As %
Student > Master	4	44%
Student > Postgraduate	1	11%
Unknown	4	44%

Readers by discipline	Count	As %
Medicine and Dentistry	3	33%
Biochemistry, Genetics and Molecular Biology	2	22%
Nursing and Health Professions	1	11%
Unknown	3	33%

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)